Comparative Pharmacology
Head-to-head clinical analysis: CHLORPROMAZINE HYDROCHLORIDE INTENSOL versus SONAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORPROMAZINE HYDROCHLORIDE INTENSOL versus SONAZINE.
CHLORPROMAZINE HYDROCHLORIDE INTENSOL vs SONAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chlorpromazine is a phenothiazine antipsychotic that blocks postsynaptic dopamine D2 receptors in the central nervous system, particularly in the mesolimbic and mesocortical pathways. It also exhibits antagonism at serotonin 5-HT2, histamine H1, alpha-1 adrenergic, and muscarinic receptors, contributing to its sedative, antiemetic, and hypotensive effects.
Sonazine is an antipsychotic agent that blocks postsynaptic dopamine D2 receptors in the mesolimbic system, with additional antagonist activity at D1, alpha1-adrenergic, histaminergic H1, and muscarinic M1 receptors.
Oral: 25-50 mg 2-3 times daily, up to 1000 mg/day in severe psychosis. IM: 25-50 mg every 1-4 hours until controlled, then switch to oral.
10-20 mg intramuscularly or intravenously every 4-6 hours as needed; maximum 100 mg/day.
None Documented
None Documented
15-30 hours; prolonged in elderly and hepatic impairment; active metabolites (e.g., 7-hydroxychlorpromazine) have longer half-lives (up to 12-24 hours)
Terminal elimination half-life: 24-36 hours; clinical context: allows once-daily dosing, steady state achieved in 5-7 days, prolongation in elderly or hepatic impairment
Renal (70-80% as metabolites, <1% unchanged); biliary/fecal (~20-30%)
Renal (70-80% as metabolites, <1% unchanged); fecal (15-20% via biliary elimination)
Category C
Category C
Antipsychotic
Antipsychotic